In Brief: Urologix/Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Urologix/Boston Scientific: Enter distribution agreement under which Boston Scientific obtains exclusive right to market Urologix' T3 (Transurethral Thermo-ablation Therapy) system for treatment of benign prostatic hyperplasia in all markets outside the U.S. and Japan. BSC begins exhibiting the T3 system at the British Association of Urological Surgeons meeting the week of June 24 in Edinburgh, Scotland. In the U.S., Urologix plans to submit a premarket approval application later this year for the T3 system. Nihon Kohden holds marketing rights in Japan, where an application for marketing approval already is pending...
You may also be interested in...
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.